Cannabis for PTSD: Promising Biology, Very Little Proof It Actually Works as Treatment

The biological case for cannabis helping PTSD was compelling. The endocannabinoid system is deeply involved in fear extinction, stress response, and emotional memory processing — exactly the mechanisms disrupted in PTSD. Animal studies showed cannabinoids could facilitate fear extinction and reduce anxiety-like behavior.

But the clinical evidence didn't match the biology. Treatment outcome studies of whole-plant cannabis for PTSD were limited and methodologically weak. The one area with real signal was nightmares: nabilone, a synthetic cannabinoid, showed benefit for PTSD-related nightmares and sleep disruption. Beyond that, the cupboard was nearly bare.

Meanwhile, the potential harms were better documented than the benefits. Cannabis use was associated with worse outcomes in depression, anxiety, psychosis, and substance misuse — conditions that frequently co-occur with PTSD. The review found stronger evidence for marijuana's harmful effects on psychosis and substance misuse development than for its therapeutic effects on PTSD itself.

This review captured a tension that still exists: the biology says the endocannabinoid system should be a therapeutic target for PTSD, but giving people cannabis or THC is a blunt tool for a precise problem. The distinction between "the endocannabinoid system is involved in PTSD" and "smoking weed treats PTSD" is enormous, and this paper drew that line clearly.

The finding that evidence for harm was actually stronger than evidence for benefit was particularly important. Many veterans and trauma survivors were already self-medicating with cannabis based on the biological plausibility alone, without knowing the clinical evidence hadn't caught up.